What drug, sevabertinib, received breakthrough therapy designation from the FDA in January 2026 for first-line treatment of NSCLC with HER2 mutations?

Sevabertinib, also known by its brand name Hyrnuo, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) in January 2026 for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors harbor activating HER2 (ERBB2) mutations. This designation highlights the potential of sevabertinib to offer a significant improvement over existing therapies for this specific patient population, which has historically faced limited treatment options.

Breakthrough Therapy Designation is a program designed to expedite the development and review of drugs for serious or life-threatening conditions. To qualify, preliminary clinical evidence must demonstrate that the drug may offer substantial improvement on at least one clinically significant endpoint over available therapies. This designation provides drug developers with more intensive FDA guidance and a potentially faster path to market, aiming to bring promising treatments to patients sooner.

Sevabertinib is an oral, reversible, small molecule tyrosine kinase inhibitor (TKI) that specifically targets HER2-activating mutations, including HER2 exon 20 insertions and point mutations. It also shows activity against epidermal growth factor receptor (EGFR) mutations, while largely sparing wild-type EGFR, which helps to minimize side effects. The Breakthrough Therapy Designation for sevabertinib was supported by positive preliminary efficacy and safety data from the SOHO-01 clinical trial, particularly from patients who were new to systemic therapy for advanced disease. In November 2025, sevabertinib had already received accelerated FDA approval for previously treated advanced HER2-mutant NSCLC.

The granting of Breakthrough Therapy Designation for sevabertinib as a first-line treatment is a significant step forward, offering new hope for patients with HER2-mutant NSCLC. This targeted approach represents a shift towards more personalized medicine, addressing a molecular subset of lung cancer that has long needed effective upfront treatment options.